title: Genes of intestinal Escherichia coli and their relation to the inflammatory activity in patients with ulcerative colitis and Crohn's disease.
abstract: Escherichia coli gene fimA was the most frequent gene that occurred in the intestine of all investigated groups. All subjects with fimA gene had significantly higher values of tumor necrosis factor alpha (TNF-α) and CRP than those with other E. coli genes. There was also a tendency to increased serum interleukin (IL)-6 levels in patients carrying the fimA gene; however, no relation was observed to serum IL-8 and IL-10. Patients with Crohn's disease had significantly higher IL-6 than those with ulcerative colitis (UC) and controls. The highest levels of TNF-α were detected in the UC group. There were no significant differences in serum IL-8 and IL-10 between all three groups. The presence of E. coli gene fimA in the large bowel of patients with IBD is related to the immunological activity of the disease which may be important from the aspect of therapeutical strategy.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, P.J. Šafárik University, Trieda SNP 1, 040 11, Košice, Slovakia. lauragombosova@yahoo.com
authors.forename: Laura
authors.initials: L
authors.lastname: Gombošová
authors.forename: I
authors.initials: I
authors.lastname: Lazúrová
authors.forename: M
authors.initials: M
authors.lastname: Zakuciová
authors.forename: K
authors.initials: K
authors.lastname: Curová
authors.forename: M
authors.initials: M
authors.lastname: Kmeťová
authors.forename: D
authors.initials: D
authors.lastname: Petrášová
authors.forename: L
authors.initials: L
authors.lastname: Siegfried
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015373:Bacterial Typing Techniques; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D018153:Czech Republic; D004926:Escherichia coli / Q000235:genetics* / Q000276:immunology; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D005260:Female; D036781:Fimbriae Proteins / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D016753:Interleukin-10 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis; D007422:Intestines / Q000276:immunology / Q000382:microbiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; C063055:fimbrillin; D016753:Interleukin-10; D036781:Fimbriae Proteins